#Autologous Stem Cell and Non-Stem Cell-Based Therapies Market 2024 | Explore Tumblr Posts and Blogs

marketresercher · 1 month

Text

Autologous Stem Cell and Non-Stem Cell-Based Therapies Market Size Advanced Technologies & Growth Opportunities in Global Industry by 2030

****Everything You Need to Know About Autologous Stem Cell and Non-Stem Cell-Based Therapies everything is Here....!

The Comprehensive study on Autologous Stem Cell and Non-Stem Cell-Based Therapies Market includes historical data as well as share, size, and projection information for the major players, geographies, applications, and product categories for the years 2024 to 2030. The Market study includes comprehensive insights on the competitive environment, description, broad product portfolio of key players, SWOT analysis, and significant business strategy implemented by rivals, revenue, Porters Five Forces Analysis, and sales projections. The report also features an impact analysis of the market dynamics, highlighting the factors currently driving and limiting market growth, and the impact they could have on the short, medium, and long-term outlook. The main goal of the paper is to further illustrate how the latest scenario, the economic slowdown, and war events affect the market for Autologous Stem Cell and Non-Stem Cell-Based Therapies.

Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is growing at a +14.61% CAGR during the forecast period 2024-2030. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

The Top Key Players profiled in the report:

BrainStorm Cell Limited, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science Inc., Opexa Therapeutics Inc., Orgenesis Inc, Regeneus Ltd., U.S. Stem Cell Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc.

Click the link to get a free sample copy of the report :

(*If you have any special requirements, please let us know and we will provide you with the report as you wish.)

Autologous Stem Cell and Non-Stem Cell-Based Therapies Market Segmentation:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Type, 2020-2029, (USD Billion).

Autologous Stem Cell

Autologous Non-Stem Cell

Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Application, 2020-2029, (USD Billion).

Cancer

Neurodegenerative Disorders

Cardiovascular Disease

Orthopedic Diseases

Based on geography, the global market for Autologous Stem Cell and Non-Stem Cell-Based Therapies and Disruptions has been segmented as follows:

North America (United States, Canada, Mexico)

South America (Brazil, Argentina, Ecuador, Chile)

Asia Pacific (China, Japan, India, Korea)

Europe (Germany, UK, France, Italy)

Middle East Africa (Egypt, Turkey, Saudi Arabia, Iran) and more.

Strategic Points Covered in Autologous Stem Cell and Non-Stem Cell-Based Therapies Market Directory:

To study and analyze the global market size (value & volume) by company, key regions/countries, products and application, history data, and forecast to 2030.

To understand the structure of market by identifying its various sub segments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the growth trends, future prospects, and their contribution to the total market.

To project the value and volume of submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Autologous Stem Cell and Non-Stem Cell-Based Therapies

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the Autologous Stem Cell and Non-Stem Cell-Based Therapies market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Autologous Stem Cell and Non-Stem Cell-Based Therapies

Take a look at the full report with detailed TOC here:

Some of the key questions scrutinized in the study are:

Which companies are expanding litanies of products with the aim to diversify product portfolio?

Which companies have drifted away from their core competencies and how have those impacted the strategic landscape of the Autologous Stem Cell and Non-Stem Cell-Based Therapies market?

Which companies have expanded their horizons by engaging in long-term societal considerations?

Which firms have bucked the pandemic trend and what frameworks they adopted to stay resilient?

What are the marketing programs for some of the recent product launches?

We offer customization on the Autologous Stem Cell and Non-Stem Cell-Based Therapies market report based on specific client requirements:

20% free customization.

Five Countries can be added as per your choice.

Five Companies can add as per your choice.

Free customization for up to 40 hours.

After-sales support for 1 year from the date of delivery.

Get More: https://exactitudeconsultancy.com/primary-research/

Thank you for your interest in the Autologous Stem Cell and Non-Stem Cell-Based Therapies Market research publications; you can also get individual chapters or regional/country report versions such as Germany, France, China, Latin America, GCC, North America, Europe or Asia……

Other Reports:

Bed Monitoring System & Baby Monitoring System market

Immunoprecipitation market

Laparoscopic and Open Hernia Mesh Repair Surgery market

Empty Capsules market

Neurodiagnostics market

About Us:

Exactitude Consultancy is a Market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you. So, whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact: Exactitude Consultancy PHONE NUMBER +1(704) 266-3234

EMAIL ADDRESS: [email protected]

0 notes

helthcareheven · 27 days

Text

Healing from Within: Autologous Stem Cell Therapies Market Assessment

The Autologous Stem Cell and Non-Stem Cell Based Therapies Market involves the use of stem cells and non-stem cell-based medical procedures for treating a variety of diseases. Autologous stem cell therapy involves extracting stem cells from a patient's own bone marrow or blood, multiplying them in the laboratory, and infusing them back into the patient. Non-stem cell based therapies include platelet-rich plasma therapy and fat grafting which are increasingly used in orthopedics, dermatology, cardiology and other clinical areas. The global market for autologous stem cell and non-stem cell-based therapies is driven by the growing prevalence of chronic diseases like cardiovascular diseases and diabetes due to a rising geriatric population worldwide.

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is estimated to be valued at US$ 98.8 Bn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030. Key players operating in the Autologous Stem Cell and Non-Stem Cell Based Therapies are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. These players are focusing on developing advanced therapeutics and improving their manufacturing and processing capabilities. For instance, BrainStorm Cell Therapeutics is developing NurOwn, an autologous mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis and multiple sclerosis. The growing demand for autologous stem cell and non-stem cell therapies is attributed to the rising preference for minimally invasive procedures coupled with the ability of these therapies to heal damaged tissues without major surgical interventions. Additionally, the increasing successful commercialization of fat grafting procedures for breast augmentation and growing popularity of PRP injections for cosmetic procedures are favoring market growth. Furthermore, increased strategic collaborations between industry players and research organizations are helping expand the global footprint of autologous stem cell and non-stem cell based therapies. For example, Fibrocell Science partnered with Castle Creek Pharmaceuticals to commercialize FCX-007, an autologous fibroblast cell therapy candidate for the treatment of moderate to severe rhinoconjunctivitis. The rising geriatric population globally is the major market driver for autologous stem cell and non-stem cell based therapies. According to the UN’s World Population Prospects 2019, the share of global population aged 65 years or above is expected to rise from 9% to 16% between 2019 and 2050. This growing aging demographic is expected to increase the incidence of chronic health conditions like cancer, orthopedic disorders, and cardiovascular diseases, thereby driving demand for advanced treatment options like stem cell and non-stem cell therapies over the forecast period. Europe accounts for the largest share of autologous stem cell and non-stem cell based therapies market in terms of value. This is mainly because of the significant research focus and advances in cell therapies in countries like Germany, UK and France. The region also has universal healthcare systems that provide insurance coverage for costly stem cell transplant procedures. North America follows Europe with substantial market presence led by the US. However, Asia Pacific region is emerging as the fastest growing market globally. This is attributed to rising healthcare expenditure, growing medical tourism and increasing awareness about regenerative medicines in highly populous countries like China and India providing immense future opportunities.

#StemCellInnovation #PersonalizedHealing #NextGenTherapies

0 notes

researchgroupreports · 2 months

Text

Cell Therapy Market Report 2024, Size, Growth, Outlook 2032

IMARC Group, a leading market research company, has recently releases report titled “Cell Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032” offers a comprehensive analysis of the industry, which comprises insights on the cell therapy market report. The global market size reached US$ 13.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 50.5 Billion by 2032, exhibiting a growth rate (CAGR) of 15.28% during 2024-2032.

Request For Sample Copy of Report: https://www.imarcgroup.com/cell-therapy-market/requestsample

Factors Affecting the Growth of the Cell Therapy Industry:

Increasing Prevalence of Chronic Diseases:

The rising prevalence of chronic diseases, such as cancer, diabetes, cardiovascular disorders, and autoimmune conditions, is propelling the growth of the market. Conventional treatments for many of these diseases often provide limited efficacy. As a result, there is an increase in the demand for innovative and more effective therapies, such as cell therapy. Cell therapy provides a targeted and personalized approach to treating chronic diseases. By harnessing the own cells of patients or using engineered cells, these therapies can address the specific underlying causes of the disease, potentially offering better outcomes compared to traditional treatments.

Advancements in Biotechnology:

Biotechnological innovations are improving the ability to characterize and understand various cell types at a molecular level. This understanding allows for the precise selection and manipulation of cells for therapy, increasing the effectiveness of cell-based treatments. Biotechnology is leading to advanced techniques like CRISPR-Cas9, which enable precise gene editing and cell engineering. This capability allows for the creation of specialized cells with enhanced therapeutic properties, making cell therapies more targeted and potent. Biotechnological advancements are streamlining the process of growing and manufacturing cells for therapy.

Rising Demand for Personalized Medicine:

Personalized medicine can provide treatments that are specifically customized as per individual patients based on their unique genetic, molecular, and clinical profiles. Cell therapy aligns with this approach by offering the potential to create therapies that are precisely matched to the needs of patients. Advancements in genomics and biomarker research are enabling the identification of genetic mutations and biomarkers associated with diseases. Cell therapies can be designed to target these specific genetic factors, making them a key component of personalized treatment strategies.

Leading Companies Operating in the Global Cell Therapy Industry:

AlloSource

Anterogen Co. Ltd.

Cells for Cells

Holostem Terapie Avanzate S.r.l.

JCR Pharmaceuticals

Kolon TissueGene Inc

MEDIPOST

Mesoblast Limited

NuVasive

Stemedica Cell Technologies Inc.

Stempeutics Research Pvt. Ltd

Vericel Corporation

Cell Therapy Market Report Segmentation:

By Cell Type:

Stem Cell

Bone Marrow

Blood

Umbilical Cord-Derived

Adipose-Derived Stem Cell

Others

Non-stem Cell

Stem cells represented the largest segment due to their versatility and potential to differentiate into various cell types.

By Therapy Type:

Autologous

Allogeneic

Autologous accounted for the largest market share on account of its reduced risk of immune rejection.

By Therapeutic Area:

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

Malignancies exhibit a clear dominance in the market as cell therapies, particularly CAR-T cell therapies, are used in treating certain types of cancer.

By End User:

Hospitals and Clinics

Academic and Research Institutes

On the basis of end user, the market has been bifurcated into hospitals and clinics and academic and research institutes.

Regional Insights:

North America (United States, Canada)

Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

Latin America (Brazil, Mexico, Others)

Middle East and Africa

North America enjoys the leading position in the cell therapy market due to a well-established healthcare infrastructure.

Global Cell Therapy Market Trends:

There is a growing number of cell therapy products in various stages of development, reflecting the increasing interest and investment in this field. The increasing demand for immunotherapies, including CAR-T cell therapies and immune checkpoint inhibitors, is strengthening the growth of the market.

Cell therapies are increasingly integrated into personalized medicine approaches, with treatments tailored as per individual patients based on genetic and molecular profiles.

Other Key Points Covered in the Report:

COVID-19 Impact

Porters Five Forces Analysis

Value Chain Analysis

Strategic Recommendations

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

#cell therapy market

0 notes

anitakumarigrewal · 4 years

Link

The autologous cell therapy belongs to the field of recreating medicine and is based on the biologic cell based therapies to treat several syndromes, involving those of the oncology, neurology and dermatology, to name a few. Autologous cell therapy is one of the fastest augmenting sectors of the regenerative medicine and therefore, is attracting increasingly research funds from the several quarters.

During the near years, it is anticipated that the worldwide autologous cell therapy market present an extensive competitive atmosphere. The important players in the market are contributing in joint ventures, takeovers, mergers, and acquisitions so as to increase entry in the local market. Corporates are also setting up manufacturing units and subsidiaries in the underdeveloped nations and this will underwrite to the market for autologous cell therapy becoming tremendously competitive in the near future. According to the report analysis, ‘Global Autologous Cell Therapy Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use’ states that in the worldwide autologous cell therapy market, there are numerous players which presently working more actively for leading the fastest market growth and dominating the high value of market share around the globe during the short span of time while increasing the applications of cure, decreasing the price, delivering the better consumer satisfaction, adopting the profit making strategies and polices and spreading the awareness related to the applications of such includes BioTime, Inc., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Fibrocell Science, Inc., Opexa Therapeutics, Inc., Pharmicell Co., Inc., Regeneus Ltd., TiGenix NV, TxCell SA, U.S. Stem Cell, Inc., Vericel Corporation and several others.

Although, based on the application segment, the worldwide market of autologous cell therapy is sectored into Neurology, Orthopedics, Cancer, Wound Healing, CVD, Autoimmune, and several others. Whereas, the segment of type involves Bone Marrow and Epidermis. Bone Marrow Segment is predicted to control the Principal Market Share in the Global Autologous Cell Therapy Market. Bone marrow transplant is a method for replacing scratched and destroyed cells with new stem cells in the bone marrow. Bone marrow is the most frequently utilized for autologous cell therapy as it can advantage individuals with a range of cancer (malignant) and non-cancer (benign) diseases and will influence the market during the forecast duration.

Moreover, the foremost aspects accrediting to the growth of the autologous cell therapy market are the increasing incidence of chronic diseases such as autoimmune diseases, cancer, blood disorder, and several others. An effective growth in the population suffering from chronic syndromes is also propelling the requirement for market growth. In 2018, as per the AARDA (American Autoimmune Related Diseases Association) statistics, nearby 50 million Americans have an autoimmune disease, and this number is predicted to grow in the future. As per the CDC (Centers for Disease Control and Prevention) predicts Sickel Cell Disease (SCD) affects around 100,000 Americas yearly. And there are few more aspects which are playing critical roles in taking the autologous cell therapy market to the next level, among them one is on-going drug advancements for new submissions which are anticipated to further drive the growth of the autologous cell therapy market.

Therefore, in the near years, it is anticipated that the market of autologous cell therapy will increase around the globe over the coming future more increasingly.

For More Information, click on the link below:-

Global Autologous Cell Therapy Market Research Report

Related Reports:-

Global Autologous Cell Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Autologous Cell Therapy Market Research: Global Status & Forecast by Geography, Type & Application (2015-2025)

Ken Research

Ankur Gupta, Head Marketing & Communications

[email protected]

+91-9015378249

#全球自体细胞治疗市场

0 notes

pharmaphorumuk · 4 years

Text

Merck’s last-resort antibiotic Recarbrio nears EU approval

Merck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should be reserved for use in patients with limited treatment options.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) backed approval of Recarbrio at its meeting last week, a few months after the drug was approved by the FDA for complicated urinary tract and intra-abdominal infections (cIAI).

The new drug combines the active ingredients in MSD’s broad-spectrum antibiotic Primaxin (imipenem/cilastatin) with a new beta lactamase inhibitor called relebactam that is designed to restore susceptibility to imipenem in resistant strains.

Drugs in the carbapenem class like imipenem have become last-line treatments for a number of multidrug resistant (MDR) infections, so Recarbrio could offer a fallback option in people with serious infections.

The CHMP notes that Recarbrio should only be prescribed “after consultation with a physician with appropriate experience in the management of infectious diseases” and with consideration to “official guidance on the appropriate use of antibacterial agents.”

The drug targets Gram-negative pathogens like Enterobacter cloacea, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Recarbrio’s reserved status means that it won’t be a big seller for MSD, with Cowen & Co analysts expecting sales to reach around $150 million in 2024, but it will be an important new option for patients.

The low returns on new antibiotic research have driven a lot of the multinational drugmakers out of the category, raising fears that MDR will become rampant and society could enter a post-antibiotic age where once-trivial infections can be life-threatening.

That disincentive is one of the factors behind a new UK proposal for a new payment system for antibiotics that will see companies paid upfront for access to new antibiotics based on their value to the NHS, rather than the volume of medicines sold.

Recarbrio was one of five new medicines recommended for approval by the CHMP at its latest meeting, along with Novartis’ wet age-related macular degeneration (AMD) therapy Beovu, Accord Healthcare’s generic versions of azacitidine for blood cancers and sedative dexmedetomidine, and Pfizer’s Amsparity – a biosimilar of AbbVie’s immunology blockbuster Humira (adalimumab).

There were also several new positive opinions on already-marketed drugs, including:

Janssen-Cilag’s Darzalex (daratumumab) for use in combination with Takeda’s Velcade (bortezomib), thalidomide and dexamethasone for adult patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant;

A new 61 mg soft capsule formulation of Pfizer’s Vyndaqel (tafamidis) for the treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM);

Extending the age-range for children with plaque psoriasis eligible for treatment with Janssen-Cilag’s Stelara (ustekinumab) to six years and over from 12 and over;

Extending the age range for treatment with Janssen-Cilag’s pulmonary multidrug‑resistant tuberculosis (MDR‑TB) therapy Sirturo (bedaquiline) to include adolescents aged over 12 as well as adults;

New oral and intravenous infusion formulations of Helsinn Birex Pharma’s Akynzeo (fosnetupitant/palonosetron) for prevention of chemotherapy-induced nausea and vomiting (CINV);

Eli Lilly’s Cyramza (ramucirumab) in combination with Roche’s Tarceva (erlotinib) for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating EGFR mutations;

A new film-coated formulation of Astellas’ Dificlir (fidaxomicin) that extends the use of the Clostridioides difficile infection (CDI) drug to include children weighing over 12.5 kg as well as adults.

The post Merck’s last-resort antibiotic Recarbrio nears EU approval appeared first on .

from https://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/

0 notes

thekwandae-blog · 5 years

Text

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2019 Outlook – Ready for Prosperous Growth by Revenue till 2024 | Exclusively Available at acquiremarketresearch.com

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market has been brewing up and impacting the international economy in terms of growth rate, revenue, sale, market share, and size. The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report renders lucid explanation to the reader to study fundamental attributes of Autologous Stem Cell and Non-Stem Cell Based Therapies industry which includes lucrative business strategies, market demands, leading player of the market, and futuristic perspective through various angles. Get Sample of Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research Report at: [click here] As the Autologous Stem Cell and Non-Stem Cell Based Therapies industry has been exhibiting substantial growth rate over the previous decade and expected to perform vigorously in forthcoming decades, it is being necessary to identify all investment opportunities, upcoming market threats, challenges, restraining factors, market dynamics, and technological advancements to strengthen footholds in Autologous Stem Cell and Non-Stem Cell Based Therapies industry. The proposed research has studied all the above elements to render a thorough analysis to the reader that drives to achieve expected growth in their businesses. Why B2B Companies Worldwide Rely on us to Grow and Sustain Revenues: • Get a clear understanding of the Autologous Stem Cell and Non-Stem Cell Based Therapies market, how it operates and the various stages of the value chain. • Understand the current market situation and future growth potential of the Autologous Stem Cell and Non-Stem Cell Based Therapies market till 2019 and plan strategies to gain from it. • Strategize marketing, market-entry, market expansion, and other business plans by understanding factors influencing growth in the market and purchase decisions of buyers. • Understand your competitor’s business structures, strategies and prospects, and respond accordingly. • Make more informed business decisions with the help of insightful recommendations provided to succeed in the Autologous Stem Cell and Non-Stem Cell Based Therapies market. Browse Full Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report @ [click here]

Market Players: ANTRIA (CRO) (U.S.), BIOHEART (U.S.), BRAINSTORM CELL THERAPEUTICS (U.S.), CYTORI (U.S.), DENDREON CORPORATION (U.S.), FIBROCELL (U.S.), GENESIS BIOPHARMA (U.S.), GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.), NEOSTEM (U.S.), OPEXA THERAPEUTICS (U.S.), ORGENESIS (U.S.), REGENEXX (U.S.), REGENEUS (AUSTRALIA), TENGION (U.S.), TIGENIX (BELGIUM), VIRXSYS (U.S.) By Type: Autologous Stem Cell, Non-Stem Cell, By Application: Medical Centers and Universities, Clinical Laboratories, Market Analysis by Geographies: This report is segmented into key Regions North America, Europe, China, Japan, Southeast Asia & India with Production Development, Sales, and Regional Trade & Forecast. Get Discount on this Report: [click here] The report elaborates competitive landscape considering mergers and acquisitions, joint ventures, partnerships, wind ups, strategic alliances, product developments, latest technological advancement, and research and developments in global Autologous Stem Cell and Non-Stem Cell Based Therapies industry along with a forecast of emerging industry trends up to 2024. Additionally, the report discusses lucrative business strategies of market competitors by lightning specific moves of competitors including business expansion, amalgamations, partnership deals, new product/service launches, and recently adopted technologies. If you have any customized requirement need to be added, we will be happy to include this free of cost to enrich the final study. For Any Query, Speak to Expert: [email protected]

#Autologous Stem Cell and Non-Stem Cell Based Therapies Market #Autologous Stem Cell and Non-Stem Cell Based Therapies #amr

0 notes

digitalkory-blog · 5 years

Text

2019-2024 Global and Regional Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report

HNY Research projects that the Autologous Stem Cell and Non-Stem Cell Based Therapies market size will grow from USD XX Million in 2018 to USD XX Million by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2017, and the market size is projected from 2018 to 2023.

REQUEST SAMPLE REPORT : https://www.predictoreports.com/reports_details?2019-2024-Global-and-Regional-A…

View On WordPress

0 notes

vishakhaposts-blog · 6 years

Text

Tooth Regeneration Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis

Worldwide Market Reports added Latest Research Report titled "Tooth Regeneration Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis" to its Large Report database.

Global Tooth Regeneration Market, by Application (Enamel, Dentin, and Pulp), by Population Demographics (Geriatrics, Middle Aged, Adult, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to have an addressable market of be valued at US$ 6,269.8 Mn in 2024, as highlighted in a new report published by Coherent Market Insights. The tooth regenerative technique is a highly touted one since a decade. However, inadequate development in the trials until now, has created uncertainty about it in the industry. Researchers are using Dental Pulp Stem Cells (DPSCs), Stem cells from human exfoliated deciduous teeth (SHEDs), Periodontal ligament stem cells (PDLSCs), Stem cells from apical papilla (SCAPs), and Dental follicle progenitor cells (DFPCs) for the development of tooth regeneration technology.

Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/187568

Various organizations are undergoing research activities for teeth regeneration creating a new dental frontier, which in turn is expected to drive growth of tooth regeneration market over the forecast period. For instance, the researchers at Tufts School of Dental Medicine are harvesting stem cells that grow new teeth and jaw bone. Moreover, the researchers at Nottingham and Harvard University gained recognition from the Royal Society of Chemistry for their innovative approach of developing dental fillings, which stimulate teeth for self-repair.

Moreover, the stem cell tooth regeneration is expected to be an affordable option for the patients, thus creating favorable opportunities for market players. For instance, according to the survey by an information hub, Underground Heath Reporter (UHR), stem cell implants are expected to cost around US$ 2500-3500, whereas the average cost of artificial dental implants ranges from US$ 1000-5000 per tooth and require post-operative care, further augmenting the overall treatment cost.

Request for Discount @ https://www.worldwidemarketreports.com/discount/187568

Browse 8 Market Data Tables and 17 Figures spread through 123 Pages and in-depth TOC on "Tooth Regeneration Market by Application (Enamel, Dentin, and Pulp), by Population Demographics (Geriatrics, Middle Aged, Adult, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2024"

Tooth regeneration market is expected to gain traction over the forecast period, as stem cell therapies have great potential to be employed in novel regenerative protocols, owing to their differentiating qualities. Increasing number of clinical trials related to dental stem cells is expected to expand the clinical applications based on pulp and periodontal tissue regeneration, thus propelling market growth. For instance, in 2013, investigators from the Fourth Military Medical University, China, initiated a clinical trial to revitalize young immature permanent teeth with necrotic pulps using autologous stem cells from human exfoliated deciduous teeth (SHED). Moreover, the clinical trial initiated by Central Hospital, France, aims to develop a pre-vascularized tissue-engineered bone construct using human cells of a simple and non-invasive tissue source such as dental pulp.

Request for Table of Content :https://www.worldwidemarketreports.com/discount/187568

** If you have any special requirements, please let us know and we will offer you the report as you want.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

#3200

Seattle, WA 98154,

U.S

Tel: +1 415 871 0703

Email:[email protected]

Visit our website for more details:https://www.worldwidemarketreports.com

Visit our new website for latest News:https://www.industrychronicle.com

#Tooth Regeneration Market #Tooth Regeneration Market share

0 notes

poojaranjane301-blog · 6 years

Text

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report 2017 Key Regions, Size by Players, Regions

Report Analysis:

Data Bridge Market Research has published a new report titled as “Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market accounted to USD 3.59billion in 2016 growing at a CAGR of 4.46% during the forecast period of 2017 to 2024.” The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

To get more information, Ask for Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-atopic-dermatitis-treatment-market

Market Definition:

Autologous stem cell and non-stem cell are undifferentiated cells or stem cells, which are taken from an individual’s cell to be cultured and then re-introduced to the donor’s body. These therapies eliminate the usage of foreign organism cells, unlike allografts and xenografts. Autologous stem cell and non-stem cell based therapies includes umbilical cord blood stem cells and resident cardiac stem cells.

Major Market Drivers and Restraints:

· Introduction of novel autologous stem cell based therapies in regenerative medicine

· Reduction in transplant associated risks

· Prevalence of cancer and diabetes in all age groups

· Growing geriatric population

· Growing number of chronic diseases

· Increasing demand for cellular transplantation

· Government initiatives and easy regulations

· Favorable reimbursement policies

· High cost of autologous cellular therapies

· Lack of skilled professionals

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Product Type, End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast to 2024

Market Competitors:

Some of the major players operating in autologous stem cell and non-stem cell based therapies market are U.S. Stem Cell, Inc., Dendreon, Inc., Fibrocell Science, Inc., Cytori Therapeutics Inc., BrainStorm Cell Therapeutics, Genesis Biotechnology Group, Caladrius, Orgenesis Inc., Regenexx, Regeneus Ltd., Tengion, Inc., TiGenix, Antria, Inc., Vericel Corporation, Sanofi, IovanceBiotherapeutics, Inc., Mesoblast Ltd., pluristem, Med Cell Europe AG, Anova IRM Stem Cell Center, Stemedica Cell Technologies, Inc., General Electric Company, BioRestorative Therapies and StemGenexamong others.

Speak to Analyst for More Details @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Market Segmentation:

The global autologous stem cell and non-stem cell based therapies market is segmented by applications into neurodegenerative disorders, autoimmune diseases, cancer & tumors and cardiovascular diseases.

On the basis of product the market is segmented into blood pressure (BP) monitoring devices, pulmonary pressure monitoring devices and intracranial pressure (ICP) monitoring devices.

By end user the market is segmented into hospitals and ambulatory surgical center.

On the basis of geography, global autologous stem cell and non-stem cell based therapies market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.

Purchase Full Report with Details TOC @ http://databridgemarketresearch.com/reports/global-autologous-stem-cell-and-non-stem-cell-based-therapies-market/

Related Report

Global Blood Culture Test Market – Industry Trends and Forecast to 2024

Global Blood Culture Test Market By Product Type, End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-blood-culture-test-market/

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Vishal Dixit

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Investor: [email protected]

Visit Blog: http://databridgemarketresearch.com/blog/

#Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market #Autologous Stem Cell and Non-Stem Cell Based Therapies #Autologous Stem Cell and Non-Stem Cell Based Therapies Market

0 notes

healthcareanalystinsights-blog · 7 years

Text

Regenerative Medicine Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024

Regenerative medicines are medical products or active pharmaceutical ingredients that have the ability to cure or replace organs and tissues organs damaged by various factors such as aging, diseases, trauma, and can also be used to provide stability in congenital disorders. According to findings of various studies, regenerative medicines can also be useful in treating both chronic and acute disorders in terms various context of abnormalities such as cardiovascular diseases, dermal wounds, and in treatment of certain types of cancer. Furthermore, the current therapy of organ and tissue transplantation for treating organ and tissue failures can result in patient death due to limited or no donor supply and often result in severe complications in immune system. Regenerative medicine helps alleviate such issues to a major extent.

Request Sample of Regenerative Medicine Market : https://www.coherentmarketinsights.com/insight/request-sample/163

Furthermore, players in the regenerative medicine market focus on fueling growth in the pharmaceutical sector by adopting various strategies such as including the use of different materials in the preparation that can offer better results and newly generated cells or with the combination of both, in turn replacing the missing tissue and effectively serving its functions. The innate healing response of the human body can also be favored to support the regenerating activities. Age is a major factor that can affect the regeneration of the desired part, as the body’s ability to regenerate is low among adults as compared to young population or lower vertebrates. Materials play an important role in regeneration activities, as they form the basis of the growth and replacement, as they can mimic the native extracellular matrix (ECM) of tissues.

Regenerative medicine market taxonomy:

By Technology

Biomaterial

Tissue Engineering

Stem Cell Therapy

By Product Type

Cell-based products

Acellular products

By Application

Orthopedic & Musculoskeletal Disorders

Cardiology

Dermatology

Diabetes

Central Nervous System Disorders

Others

By Material

Algae Derived Alginate

Synthetic Polymer

Poly-lactide-coglycolide

poly-ethylene glycol

Hydrogels

By Agent Type

Biologics

Autologous fibroblasts

Hematopoietic stem and progenitor cells

Cell-based medical devices

Allogenic fibroblasts

Cell extraction

Biopharmaceuticals

Tri-calcium Phosphate

Osteogenic Protein

Rising number of bone and joint surgeries to fuel the growth of regenerative medicine market in the near future:

Rise in number of trauma case globally is expected to favor growth of the regenerative medicine market in the near future. There are different types of prosthetics and implants that are used to support the human body movement in case of trauma and severe injury. However, a majority of the young population perceives these to be an eye sore and are increasingly inclined towards non-obtrusive options that do not drastically alter their physical appearance and activities. Regenerative medicine provides a viable alternative to such conventional methods and also reduces risk of deformity. However, regenerative medicine is significantly expensive as compared to conventional methods of treatment. Also, this treatment option is barely effective for treatment of the geriatric population. These factors impede growth of the market to a certain extent. According to University of California, Los Angeles (UCLA) Department of Orthopedic Surgery, in 2015, around 7,515 orthopedic surgeries were conducted in the U.S. by the department from July 2014 to June 2015. This number is expected to rise due to rise in number of orthopedic trauma cases in the region, which is further projected to favor growth of the regenerative medicine market in the near future.

Developed regions major growth engines of the regenerative medicine market

Developed countries such as the U.S., Germany, U.K., France, and Japan have a highly developed market for regenerative medicine, mainly due to technical advancements in the region. According to Regenerative Medicine Annual Report, in 2013, in regenerative medicine market there has been various product approvals along with annual revenue of around US$ 1 billion. Thus, this sector is expected to attract attention from investors and industry partners in the near future. Furthermore, as per the report, around 60,000 stem cell transplants are performed globally each year to treat various cancers and blood-based disorders. This augments growth of the market of regenerative medicine. Also, as observed by Alliance for Regenerative Medicine (ARM), in 2012, the bio-therapeutic companies distributing cell therapy products generated around US$ 900 million, with 160,000 patients undergoing various related treatments.

Request the table of content : https://www.coherentmarketinsights.com/ongoing-insight/toc/163

Major acquisitions to support growth of regenerative medicine market

There are few recent acquisitions by the big brands in biotechnology that is expected to favor growth of regenerative medicine industry. In August 2016, Medtronic Inc. acquired Heart Ware International, Inc. — a provider of technologies for less-invasive, miniaturized, mechanical circulatory support (MCS) for treatment of patients with advanced heart failure. This acquisition is further expected to favor the working efficiency of the company and broadens its product portfolio. Key players operating in the regenerative medicine market include Depuy Synthes, Inc., Orthofix, Inc., NuVasive, Inc. and Zimmer Holdings, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights 1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

Website: https://www.coherentmarketinsights.com

Visit Blog : http://globalresearchtrends.blogspot.in

#Regenerative Medicine Market Regenerative Medicine Industry Insights Regenerative Medicine Market Trends

0 notes

poojaranjane301-blog · 6 years

Text

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis, Industry Research and End User 2024

Market Analysis: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

The global autologous stem cell and non-stem cell based therapies market accounted to USD 3.59billion in 2016 growing at a CAGR of 4.46% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Product Type, End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast to 2024

Request For Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-atopic-dermatitis-treatment-market

Market Definition: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Major Market Drivers and Restraints:

· Introduction of novel autologous stem cell based therapies in regenerative medicine

· Reduction in transplant associated risks

· Prevalence of cancer and diabetes in all age groups

· Growing geriatric population

· Growing number of chronic diseases

· Increasing demand for cellular transplantation

· Government initiatives and easy regulations

· Favorable reimbursement policies

· High cost of autologous cellular therapies

· Lack of skilled professionals

Speak to Analyst for More Details @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Market Segmentation: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

On the basis of product the market is segmented into blood pressure (BP) monitoring devices, pulmonary pressure monitoring devices and intracranial pressure (ICP) monitoring devices.

By end user the market is segmented into hospitals and ambulatory surgical center.

Browse Full Report with Details TOC @ http://databridgemarketresearch.com/reports/global-autologous-stem-cell-and-non-stem-cell-based-therapies-market/

Competitive Analysis: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

The autologous stem cell and non-stem cell based therapies market Analysis is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of autologous stem cell and non-stem cell based therapies market for global, Europe, North America, Asia Pacific and South America.

Major Market Competitors: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Research Methodology: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an analyst call or drop down your enquiry.

Demand Side Primary Contributors: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Report

Global Blood Culture Test Market – Industry Trends and Forecast to 2024

Global Blood Culture Test Market By Product Type, End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-blood-culture-test-market/

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Vishal Dixit

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Investor: [email protected]

Visit Blog: http://databridgemarketresearch.com/blog/

#Autologous Stem Cell and Non-Stem Cell Based Therapies Market

0 notes